Antilipolytic activity of a novel partial A1 adenosine receptor agonist devoid of cardiovascular effects: Comparison with nicotinic acid

Journal of Pharmacology and Experimental Therapeutics

Volumn 321, Issue 1, 2007, Pages 327-333

  Dhalla, Arvinder K ^a   Santikul, Melissa ^a   Smith, Michelle ^a   Wong, Mei Yee ^a   Shryock, John C ^a   Belardinelli, Luiz ^a  

^a CV THERAPEUTICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DIPROPYL 8 CYCLOPENTYL XANTHINE; 6 N CYCLOPENTYLADENOSINE; [[2 [6 (2 HYDROXYCYCLOPENTYL)AMINO]PURIN9 YL] 5 [(2FLUOROPENTYLTHIO) METHYL] OXOLANE 3,4 DIOL)]; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ALPHA1 ADENOSINE RECEPTOR AFFECTING AGENT; ALPHA1 ADENOSINE RECEPTOR INHIBITOR; CVT 3619; FATTY ACID; INSULIN; NICOTINIC ACID; TRIACYLGLYCEROL; TYLOXAPOL; UNCLASSIFIED DRUG;

ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DRUG ACTIVITY; HEART RATE; LIPOLYSIS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TACHYPHYLAXIS; TRIACYLGLYCEROL BLOOD LEVEL;

ADENOSINE; ADIPOCYTES; ANIMALS; BLOOD PRESSURE; CELL SEPARATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS, NONESTERIFIED; HEART RATE; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIPOLYSIS; MALE; NIACIN; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ADENOSINE A1; TRIGLYCERIDES;

EID: 33947401350     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.114421     Document Type: Article

References (42)

1. Arner P (2005) Human fat cell lipolysis: biochemistry, regulation and clinical role. Best Pract Res Clin Endocrinol Metab 19:471-482.
2. Bays H, Mandarino L, and DeFronzo RA (2004) Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 89:463-478.
3. Belardinelli L, Linden J, and Berne RM (1989) The cardiac effects of adenosine. Prog Cardiovasc Dis 32:73-97.
4. Blackard WG and Heidingsfelder SA (1969) Effect of adrenergic receptor blockade on nicotinic acid-induced plasma FFA rebound. Metabolism 18:226-233.
5. Boden G (2001) Obesity, free fatty acids and insulin resistance. Curr Opin Endocrinol Diab 8:235-239.
6. Boden G, She P, Mozzoli M, Cheung P, Gumireddy K, Reddy P, Xiang X, Luo Z, and Ruderman N (2005) Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-{kappa}B pathway in rat liver. Diabetes 54:3458-3465.
7. Budohoski L, Challiss RA, Cooney GJ, McManus B, and Newsholme EA (1984) Reversal of dietary-induced insulin resistance in muscle of the rat by adenosine deaminase and an adenosine-receptor antagonist. Biochem J 224:327-330.
8. Carlson LA (2005) Nicotinic acid: the broad-spectrum lipid drug: a 50th anniversary review. J Intern Med 258:94-114.
9. Carlson LA and Oro L (1962) The effect of nicotinic acid on the plasma free fatty acid; demonstration of a metabolic type of sympathicolysis. Acta Med Scand 172:641-645.
10. Chen YD, Golay A, Swislocki AL, and Reaven GM (1987) Resistance to insulin suppression of plasma free fatty acid concentrations and insulin stimulation of glucose uptake in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 64:17-21.
11. 1 adenosine receptor ligands. Curr Top Med Chem 3:369-385.
12. 1 adenosine receptor agonists. U.S. patent application number 20060009417. 2006 Jan 12.
13. 1 adenosine receptors. U.S. patent application number 20060052330. 2006 Mar 9.
14. Fain JN, Pointer RH, and Ward WF (1972) Effects of adenosine nucleosides on adenylate cyclase, phosphodiesterase, cyclic adenosine monophosphate accumulation, and lipolysis in fat cells. J Biol Chem 247:6866-6872.
15. Fatholahi M, Xiang Y, Wu Y, Li Y, Wu L, Dhalla AK, Belardinelli L, and Shryock JC (2006) A novel partial agonist of the A1-adenosine receptor and evidence of receptor homogeneity in adipocytes. J Pharmacol Exp Ther 317:676-684.
16. 1 adenosine receptor agonist, antagonizes catecholamine-induced lipolysis without cardiovascular effects in awake rats. J Pharmacol Exp Ther 305:225-231.
17. 1 adenosine receptor-G-protein complexes: effects of receptor down-regulation and phosphorylation on coupling. Biochem J 338:729-736.
18. Gardner CJ, Twissell DJ, Coates J, and Strong P (1994) The effects of GR79236 on plasma fatty acid concentrations, heart rate and blood pressure in the conscious rat. Eur J Pharmacol 257:117-121.
19. Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, Ganda OP, Rosenson RS, Buse JB, Robertson DD, et al. (2002) Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of Niaspan Trial. Arch Intern Med 162:1568-1576.
20. Hoffman BB, Chang H, Dall'Aglio E, and Reaven GM (1986a) Desensitization of adenosine receptor-mediated inhibition of lipolysis: the mechanism involves the development of enhanced cyclic adenosine monophosphate accumulation in tolerant adipocytes. J Clin Investig 78:185-190.
21. Hoffman BB, Dall'Aglio E, Hollenbeck C, Chang H, and Reaven GM (1986b) Suppression of free fatty acids and triglycerides in normal and hypertriglyceridemic rats by the adenosine receptor agonist phenylisopropyladenosine. J Pharmacol Exp Ther 239:715-718.
22. Itani SI, Ruderman NB, Schmieder F, and Boden G (2002) Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes 51:2005-2011.
23. Kelly JJ, Lawson JA, Campbell LV, Storlien LH, Jenkins AB, Whitworth JA, and O'Sullivan AJ (2000) Effects of nicotinic acid on insulin sensitivity and blood pressure in healthy subjects. J Hum Hypertens 14:567-572.
24. Kovoor A, Celver JP, Wu A, and Chavkin C (1998) Agonist induced homologous desensitization of mu-opioid receptors mediated by G protein-coupled receptor kinases is dependent on agonist efficacy. Mol Pharmacol 54:704-711.
25. Liang HX, Belardinelli L, Ozeck MJ, and Shryock JC (2002) Tonic activity of the rat adipocyte A1-adenosine receptor. Br J Pharmacol 135:1457-1466.
26. McKenny J, Proctor J, Harris S, and Chinchili V (1994) A comparison of the efficacy and toxic effects of sustained vs immediate-release niacin in hypercholesterolemic patients. J Am Med Assoc 271:672-710.
27. Pereira JN (1967) The plasma free fatty acid rebound induced by nicotinic acid. J Lipid Res 8:239-244.
28. Poynten AM, Gan SK, Kriketos AD, O'Sullivan A, Kelly JJ, Ellis BA, Chisholm DJ, and Campbell LV (2003) Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content. Metabolism 52:699-704.
29. Reaven GM (1995) The fourth musketeer: from Alexandre Dumas to Claude Bernard. Diabetologia 38:3-13.
30. Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, and Shulman GI (1996) Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Investig 97:2859-2865.
31. Rolband GC, Furth ED, Staddon JM, Rogus EM, and Goldberg AP (1990) Effects of age and adenosine in the modulation of insulin action on rat adipocyte metabolism. J Gerontol 45:B174-B178.
32. Sako Y and Grill VE (1990) A 48-hour lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and B cell oxidation through a process likely coupled to fatty acid oxidation. Endocrinology 127:1580-1589.
33. Schoelch C, Kuhlmann J, Gossel M, Mueller G, Neumann-Haefelin C, Belz U, Kalisch J, Biemer-Daub G, Kramer W, Juretschke HP, et al. (2004) Characterization of adenosine-A1 receptor-mediated antilipolysis in rats by tissue microdialysis, 1H-spectroscopy, and glucose clamp studies. Diabetes 53:1920-1926.
34. Schwabe U, Schonhofer PS, and Ebert R (1974) Facilitation by adenosine of the action of insulin on the accumulation of adenosine 3′:5′- monophosphate, lipolysis, and glucose oxidation in isolated fat cells. Eur J Biochem 46:537-545.
35. Shryock JC, Ozeck MJ, and Belardinelli L (1998) Inverse agonists and neutral antagonists of recombinant human A1 adenosine receptors stably expressed in Chinese hamster ovary cells. Mol Pharmacol 53:886-893.
36. Takasuga S, Katada T, Ui M, and Hazeki O (1999) Enhancement by adenosine of insulin-induced activation of phosphoinositide 3-kinase and protein kinase B in rat adipocytes. J Biol Chem 274:19545-19550.
37. 1 adenosine receptor of human and mouse adipose tissues: cloning, expression, and characterization. Biochem Pharmacol 58:1269-1277.
38. Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K, and Offermanns S (2003) PUMA-G and HM74 are receptors for nicotinic acid and mediate its antilipolytic effect. Nat Med 9:352-355.
39. Vachon L, Costa T, and Herz A (1987) Opioid receptor desensitization in NG 108-15 cells: differential effects of a full and a partial agonist on the opioid-dependent GTPase. Biochem Pharmacol 36:2889-2897.
40. van Schaick EA, Tukker HE, Roelen HCPF, IJzerman AP, and Danhof M (1998) Selectivity of action of 8-alkylamino analogues of N6-cyclopentyladenosine in vivo: haemodynamic versus anti-lipolytic responses in rats. British J Pharm 124:607-618.
41. Vega GL, Cater NB, Meguro S, and Grundy SM (2005) Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia. Am J Cardiol 95:1309-1313.
42. Wu L, Belardinelli L, Zablocki JA, Palle V, and Shryock JC (2001) A partial agonist of the A(1)-adenosine receptor selectively slows AV conduction in guinea pig hearts. Am J Physiol 280:H334-H343.